Last reviewed · How we verify
Sunphenon
Sunphenon is a Small molecule drug developed by H. Lee Moffitt Cancer Center and Research Institute. It is currently in Phase 2 development. Also known as: Green Tea Catechin, Green tea polyphenols, Green tea extract, Sunphenon 90DCD-T.
Sunphenon is a small molecule, specifically a form of (-)-Epigallocatechin Gallate (EGCG), which is a compound found in green tea extract. It has been studied in clinical trials for various conditions, including Type 2 Diabetes, Dyslipidemias, and Prostate Cancer, among others.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sunphenon |
|---|---|
| Also known as | Green Tea Catechin, Green tea polyphenols, Green tea extract, Sunphenon 90DCD-T |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of Green Tea Catechins in Men on Active Surveillance (PHASE2)
- Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach (PHASE3)
- Green Tea Extract for Endometriosis Treatment (PHASE2)
- Sunphenon in Progressive Forms of Multiple Sclerosis (PHASE2, PHASE3)
- Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease (PHASE2, PHASE3)
- Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) (PHASE1, PHASE2)
- Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy (PHASE2, PHASE3)
- Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sunphenon CI brief — competitive landscape report
- Sunphenon updates RSS · CI watch RSS
- H. Lee Moffitt Cancer Center and Research Institute portfolio CI
Frequently asked questions about Sunphenon
What is Sunphenon?
Who makes Sunphenon?
Is Sunphenon also known as anything else?
What development phase is Sunphenon in?
Related
- Manufacturer: H. Lee Moffitt Cancer Center and Research Institute — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Green Tea Catechin, Green tea polyphenols, Green tea extract, Sunphenon 90DCD-T
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing